DDOOD Stock UPDATES Cerebain Biotech Corp. (DDOOD) 1.6800 08/20/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cerebain Biotech Corp. (DDOOD) 1.6800 $DDOOD

Discount Dental Materials announces name change to Cerebain Biotech Corp
M2 - Fri Jun 20, 4:40AM CDT
Discount Dental Materials Inc (OTCBB DOO), announced on Thursday that it has changed its name to Cerebain Biotech Corp.

Discount Dental Materials, Inc. Changes Its Name to Cerebain Biotech Corp.
Business Wire - Thu Jun 19, 8:00AM CDT
Discount Dental Materials, Inc. (OTCBB: DDOOD), announced that it has changed its name to Cerebain Biotech Corp. ("Cerebain" or "the Company" .

Cerebain Biotech engages consultant for representation in the PRC
M2 - Wed Jan 22, 4:07AM CST
Cerebain Biotech Corp, a subsidiary of Discount Dental Materials Inc (OTCBB DOO), a discoverer of products for the treatment of Alzheimer's disease utilising Omentum, announced on Tuesday the engagement of John Ballard to represent the company in The People's Republic of China.

Cerebain Biotech Corp. Announces Engagement of Consultant for Representation in China
Business Wire - Tue Jan 21, 8:00AM CST
Cerebain Biotech Corp. ("Cerebain" or "the Company" , a subsidiary of Discount Dental Materials, Inc. (OTCBB: DDOO), announced today that it has engaged John Ballard to represent the Company in The People's Republic of China for the purpose of Clinical Testing of the Company's Medical Device for the treatment of Alzheimer's Disease utilizing the Omentum. The Consultant will serve as the intermediary in China to determine and finalize any required local approvals and establish essential partnerships with Doctors and Medical Facilities necessary for this testing once the Company's prototype is completed. The medical device is being developed by Cerebain Biotech Corp as a potential new approach for the treatment for patients suffering from Alzheimer's and Dementia.

Cerebain Biotech Corp. Announces Commencement of Discussions for Representation in Poland
Business Wire - Wed Sep 11, 8:00AM CDT
Cerebain Biotech Corp. ("Cerebain" or "the Company" , a subsidiary of Discount Dental Materials, Inc. (OTCBB: DDOO) announced today that it has commenced discussions pertaining to representation of the Company in Poland for the purpose of Clinical Testing of the Company's Medical Device for the treatment of Alzheimer's Disease utilizing the Omentum. The purpose of these discussions are to engage consultants to determine and finalize any required local approvals and establish essential partnerships with Doctors and Medical Facilities necessary for this testing once the Company's prototype is completed. The medical device is being developed by Cerebain Biotech Corp as a potential new approach to the treatment for patients suffering from Alzheimer's and Dementia.

Cerebain Biotech Releases Updated Photo of Its First Prototype of the Company's Medical Device Product for Treatment of Alzheimer's
Business Wire - Fri Aug 23, 8:00AM CDT
Cerebain Biotech Corp. ("Cerebain" or "the Company" , a subsidiary of Discount Dental Materials, Inc. (OTCBB: DDOO), announced that medical device product development company, Sonos Models, Inc. ("Sonos" , has provided additional photo of the first prototype of the Company's medical device solution for the treatment of Alzheimer's disease utilizing the Omentum.

OTC Daily Alert Stock Watch - Discount Dental Materials Inc (OTCQB: DDOO)
WorldStockWire - Wed Aug 21, 1:00AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com

Cerebain Biotech Releases Initial Photos of Its First Prototype of the Company's Medical Device Product for Treatment of Alzheimer's
Business Wire - Mon Aug 12, 5:00AM CDT
Cerebain Biotech Corp. ("Cerebain" or "the Company" , a subsidiary of Discount Dental Materials, Inc. (OTCBB: DDOO), announced that medical device product development company, Sonos Models, Inc. ("Sonos" , has provided photos of the first prototype of the Company's medical device solution for the treatment of Alzheimer's disease utilizing the Omentum.

Cerebain Biotech Corp. to Hold Conference Call
Business Wire - Sun Jun 30, 1:26PM CDT
Cerebain Biotech Corp. ("Cerebain" or "the Company" , a subsidiary of Discount Dental Materials, Inc. (OTCBB: DDOO) announced today it intends to hold a conference call on July 1st at 3:30 p.m. EST. The purpose of the call is to permit Dr. Surinder Saini, Chairman of the Company's Scientific Advisory Board, an opportunity to provide the genesis of and thought processes surrounding the Company's efforts to develop the world's first medical device specifically designed for the treatment of Alzheimer's disease utilizing the Omentum. Investors and Analysts may join the conference call by dialing 712-432-9998, and entering access code 126307#.

Cerebain Biotech Provides Medical Device Update
Business Wire - Thu Jun 27, 8:46AM CDT
Cerebain Biotech Corp. ("Cerebain" or "the Company" , a subsidiary of Discount Dental Materials, Inc. (OTCBB: DDOO), announced that medical device product development company, Sonos Models, Inc. ("Sonos" , is set to complete the first prototypes of its medical device solution during the company's first fiscal quarter, which begins July 1, 2013.

Cerebain Biotech Corp. Announces Engagement of IDC Consulting for Representation in Uzbekistan
Business Wire - Mon Jun 24, 2:43PM CDT
Cerebain Biotech Corp. ("Cerebain" or "the Company" , a subsidiary of Discount Dental Materials, Inc. (OTCBB: DDOO), announced today that it has engaged IDC Consulting to represent the Company in Uzbekistan for the purpose of Clinical Testing of the Company's Medical Device for the treatment of Alzheimer's Disease utilizing the Omentum. IDC Consulting will serve as the intermediary in Uzbekistan to determine and finalize any required local approvals and establish essential partnerships with Doctors and Medical Facilities necessary for this testing once the Company's prototype is completed. The medical device is being developed by Cerebain Biotech Corp. as a potential new approach to the treatment for patients suffering from Alzheimer's and Dementia.

Cerebain Biotech Corp. Appoints Dr. Saini Chairman of Its Scientific Advisory Board
Business Wire - Mon Jun 17, 3:09PM CDT
Cerebain Biotech Corp. ("Cerebain" or "the Company" , a subsidiary of Discount Dental Materials, Inc. (OTCBB: DDOO) announced today the appointment of Dr. Surinder Saini as Chairman of its Scientific Advisory Board. The advisory board provides key clinical insight into the company's efforts to develop and commercialize a novel approach to the treatment for patients suffering from Alzheimer's disease. Dr. Saini is the lead scientist behind the development of the world's first medical device specifically designed for the treatment of Alzheimer's disease utilizing the Omentum.

Cerebain Biotech Corp. Announces Information Available Through S&P's Corporation Records Program
Marketwire - Tue May 07, 8:01AM CDT
Cerebain Biotech Corp. ("Cerebain" or "the Company" , a subsidiary of Discount Dental Materials, Inc. (OTCBB: DDOO) announced today that its company information is available via Standard & Poor's Corporation Records Listing Program. As part of the program, a full description of Discount Dental Materials, Inc. will be published in the Daily News Section of Standard & Poor's Corporation Records, a recognized securities manual for secondary trading in up to 38 States under the Blue Sky Laws. Standard & Poor's Corporation Records is available in print, CD-ROM, and via the web at www.netadvantage.standardandpoors.com as well as through numerous electronic vendors.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Dahua's Pro Challenge 2026: Bridging Expertise Globally

Updated Category News Views 64

Celebrating Global Installer Expertise Dahua Technology took to the stage in Hangzhou for the Pro Challenge 2026, a shindig pulling installer partners from every corner of the globe. This wasn't just a tech jamboree; it was a tip of the hat to those on the ground who make Dahua's AIoT solutions tick. You know the drill: hands-on demos, tech showcases, and a whole lot of...

Continue Reading
Data Center Transformers on the Brink of a Boom

Updated Category News Views 235

A Flash Look: Powering Up Data Centers Look, if you're thinking of sidestepping data center transformers as just another cog in the machine, think again. This market's set to balloon—doubling from $5.59 billion in 2026 to a jaw-dropping $10.72 billion by 2031. We're talking a chunky 13.9% CAGR. Not every bit of news grabs you by the lapels, but this one does. What’s...

Continue Reading
Parallels Desktop: Top Dog for Windows on Mac

Updated Category News Views 75

A Simpler Way to Bridge the Mac and Windows World Seems like Parallels Desktop is once again flexing its muscles for Mac users in 2026. Expert Consumers out of New York just gave them the thumbs-up as the go-to pick for folks wanting to hitch their Mac wagon to Windows 11. And why not? Parallels lets you take a stroll through Windows land without cutting your Mac ties. A...

Continue Reading
WeFetch AI: A New Era in Barcode Precision

Updated Category News Views 46

WeFetch AI: What's in a Name? Forget about GreenCore Solutions Corp. We're talking about WeFetch AI Corp. now. They've just changed their name, fulfilling a bureaucratic tick as of November 13, 2026. But it ain't just a name change; it's a whole new ballgame in AI-driven commerce. AI Shopping Without the Guesswork We've all been there. You think you've ordered that...

Continue Reading
Greenworks Mower Snags Best Electric Award for 2026

Updated Category News Views 41

Greenworks Strikes Again with Top Lawn Mower Honors Man, when I think about the evolution from noisy, gas-guzzling lawn mowers to sleek, battery-powered beasts, Greenworks is right there, leading the charge. Just the other day, Popular Mechanics singled out the Greenworks 80V 22-inch Cordless Lawn Mower, handing it the coveted title of Best Electric Lawn Mower for 2026....

Continue Reading
ACME's AI Innovation Shakes Up Filmmaking Scene

Updated Category News Views 26

The Game-Changer in Virtual Production You ever hear about the Grey Box™ phenomenon? Sounds like a sci-fi gizmo, right? Turns out, it's the real deal and ACME Media's been riding this revolutionary wave straight to the top of the film industry ladder. Their approach with this AI-driven gizmo isn't just about cutting-edge tech wizardry—it's reimagining how we shoot...

Continue Reading
PangeAI and Sky Blue Transform Data Center Decisions

Updated Category News Views 80

Just when you thought the incessant trials of picking a prime data center site couldn’t get any more grueling or expensive, enter PangeAI and its brand-new ally, Sky Blue Impact. These tech firms have partnered up to speed up what has traditionally been a sluggish, pricey process. Here’s the deal: PangeAI’s geospatial AI platform lets Sky Blue dodge the usually...

Continue Reading
Decoding Arrest: Steps from Arraignment to Trial

Updated Category News Views 71

Someone lands in handcuffs, and it's the start of a winding road through the justice system. We're talking about the stages you gotta navigate, explained by Criminal Law Attorney Tangi Carter. If you're anywhere near Hattiesburg, Mississippi, or quite frankly, have any eye on legal matters in your backyard, you know having a roadmap is pure gold. Arraignment: The...

Continue Reading
Millrose Faces Investor Deadline in Class Action Lawsuit

Updated Category News Views 75

Shakeup at Millrose Properties: Investor Alert! Alright, folks, gather around. We got a situation brewing with Millrose Properties, Inc. (NYSE: MRP) that's catching the attention of anyone who's hauled their portfolio through the storms and sunshine of the stock market. A class action lawsuit's knocking at the door, and any daydreaming investor who snatched up shares...

Continue Reading
AppLovin Faces Serious Investor Lawsuit Deadline

Updated Category News Views 72

Investors' Trust Shaken: The AppLovin Controversy Well, what do we have here? Another day, another hefty lawsuit coming down the pike. The spotlight’s on AppLovin Corporation (NASDAQ: APP), where the Hagens Berman law sharks are sniffing blood in the water over what they claim are federal securities law violations. The core of this legal storm swirls around AppLovin's...

Continue Reading

Top 5 Most Recently Viewed Articles

Global Polymer Foam Market Trends and Insights for 2025-2034

Updated Category News Views 255

Understanding the Polymer Foam Market The polymer foam market has witnessed significant growth recently, with a valuation of USD 151.19 billion in 2024 and expectations of reaching USD 273.58 billion by 2034. This growth corresponds to a compound annual growth rate (CAGR) of 6.11% from 2025 to 2034. A substantial portion of this expansion is influenced by the increasing...

Continue Reading
Renee Gala Takes the Helm as Jazz Pharmaceuticals CEO

Updated Category News Views 249

Renee Gala Takes on Leadership at Jazz Pharmaceuticals In an exciting development for Jazz Pharmaceuticals, the Board of Directors has announced the unanimous selection of Renee Gala as the new President and Chief Executive Officer. This pivotal decision is set to take effect shortly, marking a significant transition for the company as it continues to forge its path in...

Continue Reading
Finzly Launches AI Security Layer Amid Rising Threats

Updated Category News Views 58

Bank Security in the Age of AI You'd think banks, of all places, were impenetrable fortresses. But these days, they're more like digital targets. With AI-driven attacks becoming as common as morning coffee, Finzly's introducing Assure, an AI-powered security and assurance layer. It's about as timely as ever, given the 89% spike in AI-enabled attacks seen last year. When...

Continue Reading
Fidelity National Financial Launches New Consent Solicitation

Updated Category News Views 304

Introduction to Consent Solicitation Fidelity National Financial, Inc. (NYSE: FNF) has recently announced the commencement of separate consent solicitations for its various series of Senior Notes, an initiative that aims to amend the terms of its existing indenture agreements. The company holds four series of Senior Notes—4.500% due in 2028, 3.400% due in 2030, 2.450%...

Continue Reading
Legal Insights on Hims & Hers Health, Inc. Class Action Case

Updated Category News Views 179

Understanding the Hims & Hers Health, Inc. Securities Litigation The legal landscape surrounding Hims & Hers Health, Inc. has become a focal point for investors as the recent securities fraud lawsuit unfolds. Investors have an opportunity to engage in this case, which may hold significant implications for their investments. Why This Lawsuit Matters This lawsuit,...

Continue Reading